• Xu-Yan Li, Xiao Tang, Rui Wang, Xue Yuan, Yu Zhao, Li Wang, Hai-Chao Li, Hui-Wen Chu, Jie Li, Wen-Ping Mao, Yu-Jun Wang, Zhan-Hong Tian, Jian-Hua Liu, Qin Luo, Bing Sun, and Zhao-Hui Tong.
• Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China.
• Int J Chron Obstruct Pulmon Dis. 2020 Jan 1; 15: 3051-3061.

IntroductionCurrently, there is a lack of evidence on the utilization of high-flow nasal cannula (HFNC) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) accompanied by hypercapnic respiratory failure. We aimed to explore the efficacy and safety of HFNC compared with conventional oxygen therapy (COT) in such patients.MethodsThis was a prospective, randomized, controlled trial. Patients with AECOPD with a baseline arterial blood gas pH ≥7.35, PaO2 <60 mmHg, and PaCO2 >45 mmHg were enrolled. The primary endpoint was treatment failure, which needs mechanical ventilation.ResultsA total of 320 patients were randomized to either the HFNC group (n = 160) or the COT group (n = 160). Sixteen (10.0%) patients in the HFNC group had treatment failure during hospitalization, which was significantly lower than the COT group figure of 31 (19.4%) patients (p = 0.026). Twenty-four hours after recruitment, the PaCO2 of the HFNC group was lower than that of the COT group (54.1 ± 9.79 mmHg vs 56.9 ± 10.1 mmHg, p = 0.030). PaCO2 higher than 59 mmHg after HFNC for 24 h was identified as an independent risk factor for treatment failure [OR 1.078, 95% CI 1.006-1.154, p = 0.032].ConclusionIn AECOPD patients with acute compensated hypercapnic respiratory failure, HFNC improved the prognosis compared with COT. Therefore, HFNC might be considered for first-line oxygen therapy in select patients.Trial Registration NumberClinicalTrials.Gov: NCT02439333.© 2020 Li et al.

19 keywords...

hide…